Turkmenistan IVD Registration: Same Pathway, Distinct Technical Review

1. Key takeaways

Turkmenistan has no separate registration pathway for IVD — in vitro diagnostics follow the same national registration route as devices. At the technical review level, however, IVD face 2 distinct requirements:

• Performance and verification evaluations apply separately;
• Stability test reports are an explicit dossier item for consumables with a shelf life (solutions, test kits, testing systems).

In one sentence: same pathway, but the technical review is not merged. For IVD manufacturers this means the national registration certificate is obtained through the identical application route, with no separate IVD track to select and no separate register to consult.

2. Legal basis

3. Expert insights

Insight 1: no dedicated IVD law means IVD share the same document list as devices.

Law No. 319-V does not distinguish between devices and IVD; both share the set of items covering the application form, legal status documents, production condition documents, test reports, instructions for use, labels and promotional materials. This is structurally completely different from the EU IVDR or the standalone rules for in vitro diagnostic reagents in China, and the reagent-specific dossiers that companies prepare from domestic experience need to be mapped onto this list. The mapping exercise typically shows that the generic device items are straightforward, while the reagent-specific analytical files must be reorganized to fit the shared list.

Insight 2: the stability test report is the only explicit IVD item in the document list.

In the document list, the applicable objects of the stability test report are expressly stated as consumables with a shelf life: solutions, test kits and testing systems. This is the only place in the entire list where requirements are differentiated by the physical form of the product, and it constitutes the main documentary difference between IVD and ordinary devices. Manufacturers should prepare stability protocols and summary reports at the reference lot level, aligned with the shelf life claimed on the label.

Insight 3: the independence of performance evaluation lies in the depth of review, not in the procedure.

Industry sources consistently state that IVD are subject to separate performance and verification evaluations. Separate means that review experts examine analytical performance on its own terms — precision, accuracy, detection limit, interference and stability — rather than treating it as an appendage of device performance testing. The same reviewers apply drug-side rigor to the analytical file, so reagent data must be presented with the same traceability expected of medicinal products. The analytical performance chapter of an IVD dossier must therefore be self-contained. A dossier in which analytical performance is scattered across device-style test reports will predictably draw queries and extend the review.

Insight 4: the protection of human genetics under Law No. 319-V pushes genetic IVD to a higher review intensity.

As noted in Articles 01 and 02, the law lists human genetics alongside life and health as protected objects. Genetic testing, prenatal screening and reproductive-health IVD should expect greater dossier requirements and longer communication cycles — this is the only substantive classification signal that can be read from the statutory text.

Insight 5: cold chain and shelf life exert double pressure on IVD.

IVD must satisfy the dossier requirements of stability studies and at the same time face the remaining shelf-life threshold at import (Article 38; practical estimate of 60%). Short-shelf-life reagents are significantly harder to schedule in Turkmenistan than ordinary devices, and the three segments — production, consular legalization and transport — must be calculated in a single plan. Planning should start from the claimed shelf life and work backwards through legalization and transit times, so that the remaining shelf-life threshold at import is met with margin.

4. Practical recommendations

1. Prepare the dossier on the generic device document list, then add the stability test report as the IVD-specific item.
2. Make the analytical performance chapter self-contained, covering precision, accuracy, detection limit, interference and stability.
3. For genetic and reproductive-health IVD, reserve greater dossier depth and longer cycles.
4. Schedule production and shipment of short-shelf-life reagents backwards from the remaining shelf-life threshold, coordinating with the consular legalization cycle.
5. Archive cold-chain records and transport validation as on-site corroboration of the stability claims.

5. Verification checklist

• □ IVD dossiers are prepared on the generic device list plus the stability report.
• □ The analytical performance chapter covers precision, accuracy, detection limit, interference and stability.
• □ Genetic and reproductive-health IVD have additional resources reserved.
• □ Production of short-shelf-life reagents is scheduled backwards from the remaining shelf-life threshold.
• □ Cold-chain records and transport validation have been archived.

Regulatory information verified as of October 30, 2026. The content cited in this document was checked against Law No. 319-V on Drug Provision (January 12, 2016) and the Regulation on the State Registration of Medicines and Medical Devices approved by the Ministry of Health (including the stability test report item in the document list); the separate performance and verification evaluations for IVD derive from consistent industry descriptions of current practice and are handled as practical estimates.

GRZAN support in Turkmenistan: GRZAN provides registration support to manufacturers, importers and authorized representatives for this market. Local resources can be coordinated, including licensed importing entities and authorized representative arrangements, covering national registration submission, the consular legalization chain for documents, delivery of samples, alignment with mandatory TDS certification, and customs clearance support. Service capabilities include classification judgment, selection of the registration pathway, preparation of dossiers in the national format, notarization and consular legalization, preparation of testing and stability documentation, organization of GMP and ISO 13485 evidence, variations and renewal, and vigilance and post-market maintenance. Contact: info@grzanglobal.com.